Möchten Sie immer auf dem neuesten Stand bleiben?

Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

Agios Pharmaceuticals announced it will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its 2Q results

Agios Pharmaceuticals today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately

Agios Pharmaceuticals, Inc. announced that its management team is scheduled to present at the Goldman Sachs Healthcare Conference on June 9 at 8:40 a.m. ET

Agios Pharmaceuticals will be featured in oral and poster presentations during the 30th European Hematology Association Congress on June 12-15, 2025.

Agios Pharmaceuticals today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference

Agios Pharmaceuticals today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference

Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2025.